Business Context and Reporting Period
Company: Spruce Biosciences, Inc. (SPRB)
Filing Type: Form 8-K (Current Report)
Date of Report: January 7, 2026
Reporting Period: The filing covers events occurring on January 7, 2026, and provides preliminary financial data as of December 31, 2025.
Key Financial Metrics
- Cash Position: Preliminary unaudited cash and cash equivalents as of December 31, 2025, were approximately $48.9 million.
- Debt Financing: Entered into a Loan Agreement for up to $50.0 million in term loans, with an additional discretionary tranche of up to $10.0 million.
- Interest Rate: Annual rate equal to the greater of (5.25% + Prime Rate) or 12.25%.
- Collateral: Loans are secured by a lien on all Company assets, including intellectual property.
- Equity Kickers: Issuance of a warrant to purchase up to $3.2 million of common stock and a conversion option for up to $4.0 million of loan principal.
- Upfront Costs: Paid a $400,000 commitment fee on the Closing Date.
Material Changes and Loan Structure
The Company secured significant new debt financing structured in tranches based on regulatory milestones for its lead asset, tralesinidase alfa (TA-ERT) for Sanfillipo Syndrome Type B (MPS IIIB):
- Tranche 1: $15.0 million funded within 5 business days of closing.
- Tranche 2: Up to $10.0 million available between March 1, 2026, and September 30, 2026, contingent on a key regulatory milestone.
- Tranche 3: Up to $15.0 million available between September 1, 2026, and March 31, 2027, contingent on an additional regulatory milestone.
- Tranche 4 (Discretionary): Up to $10.0 million available between October 1, 2027, and June 30, 2028, contingent on a commercial milestone and mutual agreement.
Repayment Terms: Interest-only payments for 12 months (extendable to 18 or 30 months based on funding and milestones). Principal repayment in equal monthly installments thereafter. Maturity date is July 1, 2029. A final payment of 4.00% of the aggregate commitment amount is due at maturity or prepayment.
Guidance, Risks, and Contingencies
- Use of Proceeds: Anticipated to fund the development and commercial launch of TA-ERT.
- Financial Covenants: The agreement contains no minimum cash requirements or other financial covenants.
- Equity Participation: The Lender has a participation right to invest up to $1.0 million in future equity financings on the same terms as other investors.
- Change of Control: If a change of control occurs prior to warrant issuance, the Company must pay a $6.4 million success fee in lieu of the warrant.
- Risks: Future funding tranches are contingent on achieving specific regulatory and commercial milestones. Failure to achieve these milestones would limit access to the full $50.0 million commitment.
Investor Verification Checklist
- Verify the final audited cash balance in the upcoming Form 10-K for the year ended December 31, 2025, as the $48.9 million figure is preliminary and unaudited.
- Monitor the Company's progress toward the regulatory milestones required to unlock Tranche 2 ($10M) and Tranche 3 ($15M) funding.
- Review the specific terms of the Warrant exercise price, which is capped at $84.75 or the price of the next bona fide equity financing before June 30, 2026.
- Assess the impact of the 4.00% final payment fee and potential prepayment fees (ranging from 1.0% to 3.0%) on the total cost of capital.
- Confirm the status of the "next bona fide round of equity financing" to determine the final warrant exercise price.